On Monday the United States regulator granted fast-track approval for the drug aducanumab, which will be marketed in the US as Aduhelm by biotechnology company Biogen.
The active ingredient in the drug, the aducanumab antibody, was discovered by researchers at the University of Zurich’s Institute for Regenerative Medicine and the Zurich-based biopharmaceutical company Neurimmune.
Alzheimer’s is the most common form of dementia in the elderly, affecting tens of millions of people worldwideExternal link. It is caused by deposits of proteins, called amyloid plaques, in the brain that accumulate over years and damage neurons. It results in progressive memory loss and impairment of learning, orientation, language and planning abilities.
Zurich researchers identified antibodies that neutralise amyloids and “ultimately discovered the substance called aducanumab”, the University of Zurich said in a press release on Monday eveningExternal link.
Neurimmune, a spin-off company from the university founded by two of its professors, says on its websiteExternal link that it is collaborating with Biogen and Japanese company Eisai to develop the drug.
The decision by the US Food and Drug Administration (FDA) to grant the treatment “accelerated approval” has met with some criticism. Drugs can be fast-tracked “to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need”, says the FDAExternal link.
The FDA concluded that the likely benefits of the treatment outweighed the risks of applying a therapy with limited and inconsistent clinical trial data.
Popular Stories
More
Foreign affairs
European nations snub Swiss-made weapons over Ukraine restrictions
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
Over a third of Swiss seniors suffer from loneliness as volunteer shortage worsens
This content was published on
“Loneliness has serious health consequences and significantly reduces life expectancy,” Pro Senectute warned in a press release on Sunday.
Swiss cantons could save over CHF13 billion, study shows
This content was published on
In education alone, over five billion could be saved in principle each year, according to an analysis by the University of Lausanne and consulting firm PwC.
CERN to expel 500 Russian scientists from November 30
This content was published on
The European Organization for Nuclear Research (CERN) is to cut cooperation with 500 scientists affiliated with Russian institutions from November 30.
Over 1,000 take part in memorial ride for deceased Swiss cyclist
This content was published on
Around 1,500 people took part in a memorial ride on Sunday for World Cycling Championship participant Muriel Furrer, who died after an accident.
Swiss survey shows majority want new nuclear power plants
This content was published on
More than half the Swiss population supports the government's plan to lift a ban on the construction of new nuclear power plants.
This content was published on
The majority of high level decisions in Swiss companies remains in the hands of men, says the latest Gender Intelligence Report.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Alzheimer’s vaccine candidate shows promise
This content was published on
The results, published in the latest edition of the Journal of Neuroscience, show that the vaccine impedes the appearance of a protein that is a hallmark of the disease. Beta-amyloid proteins amass in the brain when a person suffers from Alzheimer’s. These so-called plaques are considered to be a typical indicator of the disease, although…
This content was published on
There are far more people with dementia in Switzerland than previously thought – and the number is expected to double over the next 25 years.
This content was published on
But the scientists warn it could be years and plenty of money before any potential application appears on the drug market. It is believed to be the first time that a potent agent against Alzheimer’s has been extracted from a type of cyanobacteria commonly known as ‘pond scum.’ The new compound, nostocarboline, was isolated by…
Study points to shortcomings in dementia diagnosis
This content was published on
The report by the Swiss Alzheimer’s Association also warns that three-quarters of those with the mental disorder are not receiving the proper treatment. The association described the results of the study, published ahead of World Alzheimer’s Day on Tuesday, as “alarming”. It also warned that Switzerland’s health system would face an “enormous challenge” in the…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.